SARS-CoV-2 vaccine (recombinant influenza A virus vector) (State Research Center of Virology and Biotechnology VECTOR)

N/A

Report date: 2025/01/26 17:04:34

Base Information

Drug NameSARS-CoV-2 vaccine (recombinant influenza A virus vector) (State Research Center of Virology and Biotechnology VECTOR)
Drug Alias Namerecombinant influenza A virus vector vaccine (State Research Center of Virology and Biotechnology VECTOR)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesState Research Center Of Virology And Biotechnology Vector
China Registration ClassN/A

Develop Information

Active CompaniesState Research Center Of Virology And Biotechnology Vector
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A